Last checked at 
(Alliance News) - Medical prediction software developer Physiomics PLC said Monday it has signed an agreement with Nasdaq-listed biopharma firm Bicycle Therapeutics and research charity Cancer Research UK.
The project is expected to be completed during 2019 and will be focused on analysis of clinical data from a phase I/IIa clinical trial of Bicycle Therapeutics's lead program, BT1718, in solid tumours.
The trial is being sponsored by Cancer Research.
On Friday last week, Physiomics won a contract from Bicycle to provide mathematical modelling services for its immune-oncology compounds.
"We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity," said Chief Executive Officer Jim Millen.
Shares in Physiomics were down 3.3% at 2.95 pence on Monday in London.